Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled study of mesdopetam for Parkinson's disease dyskinesia
2020-002010-41Phase 2Completed
- Sponsor
- IRLAB
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesdopetam in Parkinson's disease (PD) (4 arms), sponsored by IRLAB. Primary endpoint: Change in average daily hours of ON-time without troublesome dyskinesia. Started Sep 2020; status: completed.
02
Drugs
mesdopetam
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-002010-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002010-41.